ADVA
30.6.2022 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today achieved an industry first with the introduction of its Oscilloquartz high-performance optical cesium atomic clock. The coreSync™ OSA 3300-HP is ADVA’s latest innovation in assured PNT, ushering in a new age of precise synchronization with unprecedented stability. Following ADVA’s launch of the first optical pumping timing solution two years ago, the OSA 3350 ePRC+, the OSA 3300-HP takes the technology to new levels. It has a 10-year lifetime compared to the five years offered by currently available high-performance magnetic clocks. As the market’s only high-performance optical cesium clock, the OSA 3300-HP sets a new benchmark for precision and availability, providing the resilience required for PNT assurance in critical infrastructure and empowering service providers to deliver differentiated SLA timing offerings with integrated GNSS backup. The feature-rich device has embedded Ethernet- and IP-based management as well as a user-friendly touchscreen GUI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005667/en/
“The launch of our coreSync™ OSA 3300-HP marks a key milestone in the design of atomic frequency and phase standards. After many years of extensive work in our Swiss laboratories supported by the European Space Agency, we now have a mature, state-of-the-art technology that enables a major leap in the accuracy and stability of network timing while providing a substantially longer lifetime,” said Gil Biran, GM of Oscilloquartz, ADVA. ”From 5G mobile services to mission-critical defense applications, our OSA 3300-HP will be a truly disruptive enhancement of our aPNT+™ technology. And what makes its arrival so significant is that it comes at a moment when existing synchronization solutions in fixed, wireless and cable networks are being stretched to the limit, while the threat of GNSS cyberattacks also continues to grow. Across a wide range of industries, our high-performance cesium atomic clock will meet new timing demands, create new value and open up new possibilities for PNT assurance in critical infrastructure.”
Atomic clocks offer the ultimate synchronization backup for networks that rely on GNSS-based timing, combining high accuracy with outstanding availability. Offering performance that far exceeds best-in-class magnetic cesium devices, the OSA 3300-HP is the industry’s first commercial high-performance optical cesium atomic clock. Featuring an all-digital design, it leverages optical-pumping techniques using laser diodes. This enables it to measure 100 times the number of atoms, making it radically more efficient compared to existing primary reference clock (PRC) technologies. Its product lifespan is 100% longer than competing high-performance magnetic cesium clocks; the OSA 3300-HP delivers optimum stability for over 10 years. What’s more, further to the launch of the OSA 3300-HP, ADVA is also announcing a dual-purpose enhancement of its OSA 3350 ePRC+. Now, as well as providing phase holdover as part of ePRTC systems, it can be utilized as a free-running frequency source with enhanced standard performance.
“What we’ve accomplished with our optical cesium atomic clock solutions is more than incremental innovation. Industrializing optical pumping techniques was widely considered to be impossible. But that’s what our team has achieved. Now, we’re taking precision timing to the next level, empowering networks with nanosecond accuracy and phenomenal stability,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, ADVA. “As well as meeting new sync requirements, our OSA 3300-HP will help simplify operations with its easy-to-use GUI for intuitive configuration and operation. These devices will support advances in a host of different technology fields. Able to meet the most demanding applications in data centers, financial networks, smart grids, transportation, metrology, scientific research and more, they will also be a foundation for future innovation as we continue to expand the boundaries of possibility for accuracy and stability.”
Learn more about ADVA’s OSA 3300-HP in these slides: https://adva.li/osa-3300-hp-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005667/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
